Cynata Therapeutics' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.
Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.
Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (MSC) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.
Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.
It maintained CYP's speculative buy rating and $0.67 price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。